antifungal agents

Summary

Summary: Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues.

Top Publications

  1. pmc Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance
    J Chandra
    Center for Medical Mycology, University Hospitals of Cleveland, and Department of Dermatology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Bacteriol 183:5385-94. 2001
  2. pmc Epidemiology of invasive candidiasis: a persistent public health problem
    M A Pfaller
    Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    Clin Microbiol Rev 20:133-63. 2007
  3. ncbi Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
    Peter G Pappas
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Clin Infect Dis 48:503-35. 2009
  4. ncbi Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 50:291-322. 2010
  5. pmc Hsp90 governs dispersion and drug resistance of fungal biofilms
    Nicole Robbins
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    PLoS Pathog 7:e1002257. 2011
  6. pmc Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis
    Eleftherios Mylonakis
    Division of Infectious Diseases, Massachusetts General Hospital, Gray Jackson 504, 55 Fruit St, Boston, Massachusetts 02114, USA
    Infect Immun 73:3842-50. 2005
  7. ncbi Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
    Michael A Pfaller
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Am J Med 125:S3-13. 2012
  8. ncbi Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
  9. pmc Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast
    Norman Pavelka
    Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA
    Nature 468:321-5. 2010
  10. ncbi Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi
    Leah E Cowen
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
    Science 309:2185-9. 2005

Research Grants

Detail Information

Publications360 found, 100 shown here

  1. pmc Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance
    J Chandra
    Center for Medical Mycology, University Hospitals of Cleveland, and Department of Dermatology, Case Western Reserve University, Cleveland, Ohio 44106, USA
    J Bacteriol 183:5385-94. 2001
    ..The studies described here form the basis for investigations into the molecular mechanisms of Candida biofilm biology and antifungal resistance and provide the means to design novel therapies for biofilm-based infections...
  2. pmc Epidemiology of invasive candidiasis: a persistent public health problem
    M A Pfaller
    Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    Clin Microbiol Rev 20:133-63. 2007
    ..Further research to improve diagnostic, preventive, and therapeutic strategies is necessary to reduce the considerable morbidity and mortality associated with IC...
  3. ncbi Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
    Peter G Pappas
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Clin Infect Dis 48:503-35. 2009
    ..Since 2004, several new antifungal agents have become available, and several new studies have been published relating to the treatment of candidemia, ..
  4. ncbi Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america
    John R Perfect
    Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Infect Dis 50:291-322. 2010
    ..However, if the diagnosis is made early, if clinicians adhere to the basic principles of these guidelines, and if the underlying disease is controlled, then cryptococcosis can be managed successfully in the vast majority of patients...
  5. pmc Hsp90 governs dispersion and drug resistance of fungal biofilms
    Nicole Robbins
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    PLoS Pathog 7:e1002257. 2011
    ..Thus, we establish a novel mechanism regulating biofilm drug resistance and dispersion and that targeting Hsp90 provides a much-needed strategy for improving clinical outcome in the treatment of biofilm infections...
  6. pmc Galleria mellonella as a model system to study Cryptococcus neoformans pathogenesis
    Eleftherios Mylonakis
    Division of Infectious Diseases, Massachusetts General Hospital, Gray Jackson 504, 55 Fruit St, Boston, Massachusetts 02114, USA
    Infect Immun 73:3842-50. 2005
    ..The G. mellonella-C. neoformans pathogenicity model may be a substitute for mammalian models of infection with C. neoformans and may facilitate the in vivo study of fungal virulence and efficacy of antifungal therapies...
  7. ncbi Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment
    Michael A Pfaller
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA
    Am J Med 125:S3-13. 2012
    ..resistance continues to grow and evolve and complicate patient management, despite the introduction of new antifungal agents. In vitro susceptibility testing is often used to select agents with likely activity for a given infection, ..
  8. ncbi Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
    Raoul Herbrecht
    Département d Hématologie et d Oncologie, Hopital de Hautepierre, Strasbourg, France
    N Engl J Med 347:408-15. 2002
    ..Voriconazole is a broad-spectrum triazole that is active against aspergillus species. We conducted a randomized trial to compare voriconazole with amphotericin B for primary therapy of invasive aspergillosis...
  9. pmc Aneuploidy confers quantitative proteome changes and phenotypic variation in budding yeast
    Norman Pavelka
    Stowers Institute for Medical Research, 1000 East 50th Street, Kansas City, Missouri 64110, USA
    Nature 468:321-5. 2010
    ....
  10. ncbi Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi
    Leah E Cowen
    Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA
    Science 309:2185-9. 2005
    ..During selection in a human host, drug resistance that was initially Hsp90-dependent evolved toward independence. Thus, Hsp90 can act in diverse ways to couple environmental contingency to the emergence and fixation of new traits...
  11. ncbi Plant defensins
    Bart P H J Thomma
    Centre of Microbial and Plant Genetics CMPG, Katholieke Universiteit Leuven, Kasteelpark Arenberg 20, 3001 Heverlee Leuven, Belgium
    Planta 216:193-202. 2002
    ..This review focuses on the classification of plant defensins in general and in Arabidopsis specifically, and on the mode of action of plant defensins against fungal pathogens...
  12. doi Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America
    Thomas J Walsh
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Infect Dis 46:327-60. 2008
  13. ncbi Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry
    David L Horn
    Div of Infectious Diseases, Thomas Jefferson University, Ste 210, 211 S 9th St, Philadelphia, PA 19107, USA
    Clin Infect Dis 48:1695-703. 2009
    ..Candidemia remains a major cause of morbidity and mortality in the health care setting, and the epidemiology of Candida infection is changing...
  14. ncbi Aspergillosis case-fatality rate: systematic review of the literature
    S J Lin
    Department of Pharmacy Administration, University of Illinois at Chicago, Chicago, IL, USA
    Clin Infect Dis 32:358-66. 2001
    ..Mortality is high despite improvements in diagnosis and despite the advent of newer formulations of amphotericin B. Underlying patient conditions and the site of infection remain important prognostic factors...
  15. pmc Aneuploidy and isochromosome formation in drug-resistant Candida albicans
    Anna Selmecki
    Department of Genetics, Cell Biology, and Development, University of Minnesota, 6 160 Jackson Hall, 321 Church Street SE, Minneapolis, MN 55455, USA
    Science 313:367-70. 2006
    ....
  16. ncbi Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study
    Kevin W Garey
    Department of Clinical Science and Administration, University of Houston College of Pharmacy, Houston, TX, USA
    Clin Infect Dis 43:25-31. 2006
    ..The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality...
  17. pmc PKC signaling regulates drug resistance of the fungal pathogen Candida albicans via circuitry comprised of Mkc1, calcineurin, and Hsp90
    Shantelle L LaFayette
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    PLoS Pathog 6:e1001069. 2010
    ....
  18. pmc Calcineurin controls drug tolerance, hyphal growth, and virulence in Candida dubliniensis
    Ying Lien Chen
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA
    Eukaryot Cell 10:803-19. 2011
    ..That calcineurin is required for drug tolerance and virulence makes fungus-specific calcineurin inhibitors attractive candidates for combination therapy with azoles or echinocandins against emerging C. dubliniensis infections...
  19. ncbi Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections
    William J Steinbach
    Division of Pediatric Infectious Diseases, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nat Rev Microbiol 5:418-30. 2007
    ..and the exploitation of fungal calcineurin pathways holds great promise for the future development of novel antifungal agents. This Review summarizes our current understanding of calcineurin biology in these fungal species, and its ..
  20. ncbi Antifungal agents: mechanisms of action
    Frank C Odds
    Aberdeen Fungal Group, University of Aberdeen, Department of Molecular and Cell Biology, Institute of Medical Sciences, Aberdeen AB25 2ZD, UK
    Trends Microbiol 11:272-9. 2003
    Clinical needs for novel antifungal agents have altered steadily with the rise and fall of AIDS-related mycoses, and the change in spectrum of fatal disseminated fungal infections that has accompanied changes in therapeutic ..
  21. ncbi The cell wall: a carbohydrate armour for the fungal cell
    Jean Paul Latge
    Unite des Aspergillus, Institut Pasteur, 25, rue du Dr Roux, 75015 Paris, France
    Mol Microbiol 66:279-90. 2007
    ..of most of its constitutive components, the cell wall is an attractive target for the development of new antifungal agents. Genomic as well as drug studies have shown that the death of the fungus can result from inhibition of cell ..
  22. pmc Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease
    Leah E Cowen
    Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada
    Proc Natl Acad Sci U S A 106:2818-23. 2009
    ....
  23. pmc Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance
    M A Ghannoum
    Center for Medical Mycology, University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Clin Microbiol Rev 12:501-17. 1999
    The increased use of antibacterial and antifungal agents in recent years has resulted in the development of resistance to these drugs...
  24. pmc Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin
    Sheena D Singh
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
    PLoS Pathog 5:e1000532. 2009
    ..albicans, establish an entirely new role for Hsp90 in mediating resistance to echinocandins, and demonstrate that targeting Hsp90 provides a promising therapeutic strategy for the treatment of life-threatening fungal disease...
  25. pmc Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, barcelona, Spain, from 2002 to 2003
    Benito Almirante
    Infectious Diseases Division, Hospital Universitari Vall d Hebron, Avda Vall d Hebron, 119 129, 08035 Barcelona, Spain
    J Clin Microbiol 43:1829-35. 2005
    ..Antifungal medication and catheter removal are critical in preventing mortality...
  26. pmc Evidence-based guidelines for empirical therapy of neutropenic fever in Korea
    Dong Gun Lee
    National Evidence based Healthcare Collaborating Agency, Seoul, Korea
    Korean J Intern Med 26:220-52. 2011
    ..be replaced with oral antibiotics; if the condition has deteriorated, a change of antibiotics or addition of antifungal agents should be considered...
  27. pmc Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings
    David B Meya
    Infectious Disease Institute, Makerere University, Mulago Hospital Complex, Kampala, Uganda
    Clin Infect Dis 51:448-55. 2010
    ..We sought to define the cost-effectiveness of serum cryptococcal antigen (CRAG) screening to identify persons with subclinical cryptococcosis and the efficacy of preemptive fluconazole therapy...
  28. ncbi Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery
    Terry Roemer
    Elitra Canada, Montreal, Quebec, Canada, H2X 3Y8
    Mol Microbiol 50:167-81. 2003
    ..albicans essential gene set, and their respective conditional mutant strains may be directly used as sensitive whole-cell assays for drug screening...
  29. ncbi Symbiotic bacteria protect wasp larvae from fungal infestation
    Martin Kaltenpoth
    Department of Animal Ecology and Tropical Biology and University of Würzburg, Am Hubland 97074 Würzburg, Germany
    Curr Biol 15:475-9. 2005
    ..This is the first report on the cultivation of bacteria in insect antennae and the first case of a symbiosis involving bacteria of the important antibiotic-producing genus Streptomyces...
  30. ncbi The biology and chemistry of antifungal agents: a review
    Muthu K Kathiravan
    Sinhgad College of Pharmacy, Department of Pharmaceutical Chemistry, Vadgaon Bk, Pune 410041, India
    Bioorg Med Chem 20:5678-98. 2012
    In recent years their has been an increased use of antifungal agents and has resulted in the development of resistance to drugs. Currently, use of standard antifungal therapies can be limited because of toxicity, low efficacy rates...
  31. pmc Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009
    Jan W M van der Linden
    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Emerg Infect Dis 17:1846-54. 2011
    ..0%. Our study found that multiazole resistance in A. fumigatus is widespread in the Netherlands and is associated with a high death rate for patients with invasive aspergillosis...
  32. ncbi Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study
    A M Tortorano
    Istituto di Igiene e Medicina Preventiva, Universita degli Studi, IRCCS Ospedale Maggiore, Via F Sforza 35, 20122 Milan, Italy
    Eur J Clin Microbiol Infect Dis 23:317-22. 2004
    ..9%. The survey results underline the burden of candidaemia in a wide range of patient populations, confirm the importance of non- albicans species, and provide baseline data for future surveillance studies at a European level...
  33. ncbi Update in antifungal therapy of dermatophytosis
    Aditya K Gupta
    Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Center, Toronto, ON, Canada
    Mycopathologia 166:353-67. 2008
    ..Relapse of infection remains a problem, particularly with tinea pedis/unguium. Appropriate follow-up duration and education of patients on proper foot hygiene are also important components in providing effective therapy...
  34. ncbi Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial
    Annemarie E Brouwer
    Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
    Lancet 363:1764-7. 2004
    ..We compared the fungicidal activity of combinations of these drugs for initial treatment of patients with cryptococcal meningitis...
  35. ncbi Antifungal activity of ZnO nanoparticles--the role of ROS mediated cell injury
    Anat Lipovsky
    Department of Chemistry, Kanbar Laboratory for Nanomaterials, Institute of Nanotechnology and Advanced Materials, Bar Ilan University, Ramat Gan 52900, Israel
    Nanotechnology 22:105101. 2011
    ..In light of the above results it appears that metal oxide nanoparticles may provide a novel family of fungicidal compounds...
  36. ncbi TOR and PKA signaling pathways converge on the protein kinase Rim15 to control entry into G0
    Ivo Pedruzzi
    Department of Medical Biochemistry, CMU, University of Geneva, 1211 Geneva 4, Switzerland
    Mol Cell 12:1607-13. 2003
    ..Thus, Rim15 integrates signals from at least three nutrient-sensory kinases (TOR, PKA, and Sch9) to properly control entry into G(0), a key developmental process in eukaryotic cells...
  37. pmc Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy
    Matteo Bassetti
    Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy
    PLoS ONE 6:e24198. 2011
    ..Determining factors associated with these high rates may lead to identifying measures that can help to prevent disease...
  38. pmc Regulatory circuitry governing fungal development, drug resistance, and disease
    Rebecca S Shapiro
    Department of Molecular Genetics, University of Toronto, Toronto, Ontario M5S1A8, Canada
    Microbiol Mol Biol Rev 75:213-67. 2011
    ..albicans, C. neoformans, and A. fumigatus provides a foundation for the study of a broader diversity of pathogenic fungi and a platform for the development of new therapeutic strategies for fungal disease...
  39. pmc Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial
    Joseph N Jarvis
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Infectious Diseases Unit, GF Jooste Hospital, Cape Town, South Africa
    AIDS 26:1105-13. 2012
    ..We performed a randomized controlled trial to determine whether addition of IFNγ to standard therapy increased the rate of clearance of cryptococcal infection in HIV-associated cryptococcal meningitis...
  40. pmc Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes
    Edward Sionov
    Molecular Microbiology Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, United States of America
    PLoS Pathog 6:e1000848. 2010
    ..neoformans. This adaptive mechanism in C. neoformans may play an important role in FLC therapy failure of cryptococcosis leading to relapse during azole maintenance therapy...
  41. pmc Calcineurin is essential for survival during membrane stress in Candida albicans
    M Cristina Cruz
    Department of Genetics, Duke University Medical Center, Durham, NC 27710, USA
    EMBO J 21:546-59. 2002
    ..albicans mutants, against other Candida species, or when combined with different azoles. We propose that calcineurin is part of a membrane stress survival pathway that could be targeted for therapy...
  42. ncbi European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update
    J Maertens
    Department of Hematology, Leukemia and Stem Cell Transplantation Unit, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium
    Bone Marrow Transplant 46:709-18. 2011
    ....
  43. ncbi Genetics and genomics of Candida albicans biofilm formation
    Clarissa J Nobile
    Department of Microbiology, Columbia University, New York, NY, USA
    Cell Microbiol 8:1382-91. 2006
    ....
  44. pmc Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata
    M A Pfaller
    JMI Laboratories, North Liberty, Iowa, USA
    J Clin Microbiol 50:1199-203. 2012
    The echinocandin class of antifungal agents is considered to be the first-line treatment of bloodstream infections (BSI) due to Candida glabrata. Recent reports of BSI due to strains of C...
  45. pmc Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study
    Livio Pagano
    M D Istituto di Ematologia, Universita Cattolica del Sacro Cuore, Largo Francesco Vito, 1 I 00168 Roma, Italia
    Haematologica 95:644-50. 2010
    ..The aim of this study was to evaluate prognostic factors, treatments and outcome of invasive aspergillosis in patients with acute myeloid leukemia based on data collected in a registry...
  46. pmc Calcineurin is required for pseudohyphal growth, virulence, and drug resistance in Candida lusitaniae
    Jing Zhang
    Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA
    PLoS ONE 7:e44192. 2012
    ..Our findings reveal that pseudohyphal growth is controlled by the calcineurin signaling cascade, and highlight the potential use of calcineurin inhibitors and caspofungin for emerging drug-resistant C. lusitaniae infections...
  47. pmc Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms
    G Ramage
    Department of Microbiology, Division of Infectious Diseases, The University of Texas Health Science Center at San Antonio, Texas 78245, USA
    Antimicrob Agents Chemother 45:2475-9. 2001
    ..albicans biofilms against these antifungal agents was demonstrated...
  48. pmc Candida albicans biofilms produce antifungal-tolerant persister cells
    Michael D LaFleur
    Department of Biology, Northeastern University, 360 Huntington Ave, 134 Mugar Hall, Boston, MA 02115, USA
    Antimicrob Agents Chemother 50:3839-46. 2006
    ..It remains to be seen whether attachment initiates dormancy that leads to the formation of fungal persisters. This study suggests that persisters may be largely responsible for the multidrug tolerance of fungal biofilms...
  49. ncbi Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009)
    Michael A Pfaller
    JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA
    Int J Antimicrob Agents 38:65-9. 2011
    ..Concern regarding C. glabrata must now include resistance to echinocandins as well as azole antifungal agents.
  50. pmc Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms
    Priya Uppuluri
    Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Antimicrob Agents Chemother 52:1127-32. 2008
    ..These findings reveal that calcineurin contributes to fluconazole resistance of biofilms and provide evidence that synergistic drug combinations may prove efficacious as novel therapeutic interventions to treat or prevent biofilms...
  51. pmc Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation
    Jeniel E Nett
    University of Wisconsin, Department of Medicine, Madison, WI 53705, USA
    Eukaryot Cell 10:1660-9. 2011
    ..This novel connection helps explain how pathogens in a multicellular biofilm community are protected from anti-infective therapy...
  52. pmc Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts
    C A D'Souza
    The Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada
    MBio 2:e00342-10. 2011
    ..gattii and the C. neoformans genomes. Finally, CGH revealed considerable variation in clinical and environmental isolates as well as changes in chromosome copy numbers in C. gattii isolates displaying fluconazole heteroresistance...
  53. pmc Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo
    Keunsook K Lee
    School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom
    Antimicrob Agents Chemother 56:208-17. 2012
    ..Our results suggest that the efficacy of caspofungin against C. albicans was reduced in vivo due to either elevation of chitin levels in the cell wall or acquisition of FKS1 point mutations...
  54. ncbi Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group
    S Chen
    Centre for Infectious Diseases and Microbiology, Westmead Hospital, Westmead, New South Wales, Australia
    Clin Infect Dis 31:499-508. 2000
    ..Resistance to antifungal drugs was uncommon. The epidemiology of CNVN infection has changed substantially. Clinical manifestations of disease are influenced more strongly by host immune status than by cryptococcal variety...
  55. pmc Bacterial protection of beetle-fungus mutualism
    Jarrod J Scott
    Department of Bacteriology, University of Wisconsin Madison, WI 53706, USA
    Science 322:63. 2008
    ....
  56. pmc Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007
    M A Pfaller
    Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA
    J Clin Microbiol 47:3185-90. 2009
    ..The oldest age group (> or = 80 years) had the highest proportion of BSI isolates that were C. glabrata (32%) and the lowest rate of fluconazole resistance (5%)...
  57. ncbi High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial
    Tihana Bicanic
    Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
    Clin Infect Dis 47:123-30. 2008
    ..A dosage range for AmB of 0.7-1 mg/kg per day is noted in current guidelines, but there are no data comparing 0.7 mg/kg per day with 1 mg/kg per day...
  58. ncbi Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance
    Mohammed A Al-Fattani
    Division of Infection and Immunity, Institute of Biomedical and Life Sciences, Joseph Black Building, University of Glasgow, Glasgow G12 8QQ, UK
    J Med Microbiol 55:999-1008. 2006
    ..To investigate a possible role for the matrix in biofilm resistance to antifungal agents, biofilms of C. albicans were grown under conditions of continuous flow in a modified Robbins device (MRD)...
  59. pmc Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
    T C White
    Department of Pathobiology, School of Public Health and Community Medicine, University of Washington, and Seattle Biomedical Research Institute, 98109, USA
    Antimicrob Agents Chemother 41:1482-7. 1997
    ..A compilation of the genetic alterations identified in this series suggests that resistance develops gradually and is the sum of several different changes, all of which contribute to the final resistant phenotype...
  60. pmc Efflux-mediated antifungal drug resistance
    Richard D Cannon
    Department of Oral Sciences, School of Dentistry, University of Otago, P O Box 647, Dunedin 9054, New Zealand
    Clin Microbiol Rev 22:291-321, Table of Contents. 2009
    ..Potential therapeutic approaches that could overcome azole resistance include targeting efflux pump transcriptional regulators and fungal stress response pathways, blockade of energy supply, and direct inhibition of efflux pumps...
  61. ncbi Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy
    P G Pappas
    University of Alabama at Birmingham Medical Center, Birmingham, AL 35294 0006, USA
    Clin Infect Dis 33:690-9. 2001
    ..Overall mortality was 30%, and mortality attributable to cryptococcosis was 12%. Cryptococcosis continues to be an important infection in HIV-negative patients and is associated with substantial overall and cause-specific mortality...
  62. ncbi CRZ1, a target of the calcineurin pathway in Candida albicans
    Mahir Karababa
    Institute of Microbiology, University Hospital Lausanne, CH 1011 Lausanne, Switzerland
    Mol Microbiol 59:1429-51. 2006
    ..In Candida albicans, the calcineurin pathway is involved in tolerance to antifungal agents, cation homeostasis and virulence...
  63. pmc Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins
    D M Kuhn
    Division of Infectious Diseases, Department of Medicine, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio 44106, USA
    Antimicrob Agents Chemother 46:1773-80. 2002
    ..In addition to conventional agents, we determined if new antifungal agents (triazoles, amphotericin B lipid formulations, and echinocandins) have activities against Candida biofilms...
  64. ncbi Echinocandins: a new class of antifungal
    David W Denning
    Education and Research Centre, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK
    J Antimicrob Chemother 49:889-91. 2002
  65. ncbi An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1
    Anna Selmecki
    Department of Genetics, Cell and Development, University of Minnesota, Minneapolis, MN 55305, USA
    Mol Microbiol 68:624-41. 2008
    ..Thus, the major mechanism by which i(5L) formation causes increased azole resistance is by amplifying two genes: ERG11 and TAC1...
  66. ncbi The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype
    Leah E Cowen
    Department of Molecular Genetics, University of Toronto, Medical Sciences Building, Room 4368, 1 King s College Circle, Toronto, Ontario, M5S 1A8, Canada
    Nat Rev Microbiol 6:187-98. 2008
    ..Harnessing Hsp90 holds great promise for treating life-threatening infectious diseases...
  67. pmc Changes in karyotype and azole susceptibility of sequential bloodstream isolates from patients with Candida glabrata candidemia
    Jong Hee Shin
    Department of Laboratory Medicine, Chonnam National University Medical School, 8 Hakdong Dongku, Gwangju 501 757, South Korea
    J Clin Microbiol 45:2385-91. 2007
    ..glabrata from the same patient without antifungal therapy. In addition, we confirmed that C. glabrata could acquire azole resistance during the course of fungemia in association with azole therapy...
  68. ncbi An update on antifungal targets and mechanisms of resistance in Candida albicans
    Robert A Akins
    Wayne State University School of Medicine, Departments of Biochemistry and Molecular Biology, 540 East Canfield, Detroit, Michigan 48201, USA
    Med Mycol 43:285-318. 2005
    ....
  69. pmc Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program
    Rana A Hajjeh
    Mycotic Diseases Branch, Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
    J Clin Microbiol 42:1519-27. 2004
    ..7% of isolates, and > or = 2 microg/ml for 0.4% of isolates. Our findings highlight changes in the epidemiology of Candida BSI in the 1990s and provide a basis upon which to conduct further studies of selected high-risk subpopulations...
  70. ncbi Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study
    Daniel H Kett
    Department of Medicine, Division of Pulmonary and Critical Care, The University of Miami Miller School of Medicine and Jackson Memorial Hospital, Miami, FL, USA
    Crit Care Med 39:665-70. 2011
    ..To provide a global, up-to-date picture of the prevalence, treatment, and outcomes of Candida bloodstream infections in intensive care unit patients and compare Candida with bacterial bloodstream infection...
  71. pmc Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata
    D Sanglard
    Institut de Microbiologie, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
    Antimicrob Agents Chemother 45:1174-83. 2001
    Candida glabrata has been often isolated from AIDS patients with oropharyngeal candidiasis treated with azole antifungal agents, especially fluconazole...
  72. ncbi Denture stomatitis: a role for Candida biofilms
    Gordon Ramage
    Department of Microbiology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 98:53-9. 2004
    ..To assess the contribution of Candida biofilms to the etiology of denture stomatitis...
  73. pmc Combination antifungal therapy for cryptococcal meningitis
    Jeremy N Day
    Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme Vietnam, Ho Chi Minh City, Vietnam
    N Engl J Med 368:1291-302. 2013
    ..We performed a randomized, controlled trial to determine whether combining flucytosine or high-dose fluconazole with high-dose amphotericin B improved survival at 14 and 70 days...
  74. ncbi Regulation of multidrug resistance in pathogenic fungi
    Joachim Morschhäuser
    Institut für Molekulare Infektionsbiologie, Universitat Wurzburg, Rontgenring 11, D 97070 Wurzburg, Germany
    Fungal Genet Biol 47:94-106. 2010
    ..This review summarizes our current knowledge about efflux pump-mediated drug resistance and its regulation in human-pathogenic fungi...
  75. pmc Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients
    Olivier Lortholary
    Institut Pasteur, Unité de Mycologie Moléculaire, Centre National de Référence Mycologie et Antifongiques, Paris, France
    Antimicrob Agents Chemother 55:532-8. 2011
    ..53; 95% CI = 1.43 to 4.48; P = 0.001) and with recent exposure to caspofungin (OR = 4.79; 95% CI = 2.47 to 9.28; P < 0.001). These findings could influence future recommendations for the management of candidemia...
  76. pmc Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers
    Arnaldo L Colombo
    Division of Infectious Diseases, Universidade Federal de Sao Paulo, Rua Botucatu 740, 04023 062 Sao Paulo, Brazil
    J Clin Microbiol 44:2816-23. 2006
    ..Antifungal resistance was rare, but correlation between fluconazole and voriconazole MICs suggests cross-resistance may occur...
  77. ncbi Defensins--components of the innate immune system in plants
    F T Lay
    Department of Biochemistry, La Trobe University, Bundoora, Victoria 3086, Australia
    Curr Protein Pept Sci 6:85-101. 2005
    ..This review describes the distribution, biosynthesis, structure, function and mode of action of plant defensins and reflects on their potential in agribiotechnological applications...
  78. ncbi HIV-associated cryptococcal meningitis
    Joseph N Jarvis
    AIDS 21:2119-29. 2007
  79. pmc The mechanism of antifungal action of essential oil from dill (Anethum graveolens L.) on Aspergillus flavus
    Jun Tian
    Key Laboratory of Combinatorial Biosynthesis and Drug Discovery, Ministry of Education, School of Pharmaceutical Sciences, Institute of Traditional Chinese Medicine and Natural Products, Wuhan University, Wuhan, PR China
    PLoS ONE 7:e30147. 2012
    ..In summary, the antifungal activity of dill oil results from its ability to disrupt the permeability barrier of the plasma membrane and from the mitochondrial dysfunction-induced ROS accumulation in A. flavus...
  80. pmc Differential antifungal and calcium channel-blocking activity among structurally related plant defensins
    Robert G Spelbrink
    The Donald Danforth Plant Science Center, St Louis, MO 63132, USA
    Plant Physiol 135:2055-67. 2004
    ....
  81. pmc Small cysteine-rich antifungal proteins from radish: their role in host defense
    F R Terras
    F A Janssens Laboratory of Genetics, Katholieke Universiteit Leuven, Heverlee, Belgium
    Plant Cell 7:573-88. 1995
    ..The term "plant defensins" is proposed to denote these defense-related proteins...
  82. pmc Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents
    Christopher F Hoehamer
    Department of Clinical Pharmacy, Colleges of Pharmacy and Medicine, University of Tennessee Health Science Center, Memphis, Tennessee 38163, USA
    Antimicrob Agents Chemother 54:1655-64. 2010
    ..The classes of antifungal agents most commonly used to treat Candida infections are the azoles, polyenes, and echinocandins...
  83. pmc Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity
    Armêl Plaine
    Laboratoire de Microbiologie et Genetique Moleculaire, AgroParisTech, UMR INRA 1238, UMR CNRS 2585, 78850 Thiverval Grignon, France
    Fungal Genet Biol 45:1404-14. 2008
    ..The role of two unknown GpiPs, Pga31 and Pga62 in the cell wall structure and composition was clearly demonstrated during this study...
  84. ncbi Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents
    James Riddell
    Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Infect Dis 52:648-53. 2011
    ..Because the eye is a protected compartment, penetration of systemically administered antifungal agents is highly variable...
  85. ncbi Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria
    M A Pfaller
    University of Iowa, Iowa City, United States
    Drug Resist Updat 14:164-76. 2011
    ..12 mcg/ml (I), and ≥ 0.25 mcg/ml (R). New, species-specific CBPs for Candida and the echinocandins are more sensitive to detect emerging resistance associated with fks mutations, and better able to predict risk for clinical failure...
  86. pmc Penetration of Candida biofilms by antifungal agents
    Mohammed A Al-Fattani
    Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK
    Antimicrob Agents Chemother 48:3291-7. 2004
    A filter disk assay was used to investigate the penetration of antifungal agents through biofilms containing single and mixed-species biofilms containing Candida...
  87. pmc Current perspectives on echinocandin class drugs
    David S Perlin
    Public Health Research Institute, New Jersey Medical School UMDNJ, Newark, NJ 07103, USA
    Future Microbiol 6:441-57. 2011
    ..Finally, the future for glucan synthase inhibitors looks bright with the development of new orally active compounds...
  88. pmc Resistance to echinocandin-class antifungal drugs
    David S Perlin
    Public Health Research Institute, New Jersey Medical School UMDNJ, Newark, NJ, USA
    Drug Resist Updat 10:121-30. 2007
    ..and can account for intrinsic reduced susceptibility of certain species. Fks1 mutations confer resistance in both yeasts and moulds suggesting that this mechanism is pervasive in the fungal kingdom...
  89. pmc Candicidin-producing Streptomyces support leaf-cutting ants to protect their fungus garden against the pathogenic fungus Escovopsis
    Susanne Haeder
    Department of Bio Organic Chemistry, Max Planck Institute for Chemical Ecology, Hans Knoll Strasse 8, D 07745 Jena, Germany
    Proc Natl Acad Sci U S A 106:4742-6. 2009
    ..This suggests that candicidins play an important role in protecting the fungus gardens of leaf-cutting ants against pathogenic fungi...
  90. ncbi Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    Thomas J Walsh
    National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 346:225-34. 2002
    ..Patients with neutropenia and persistent fever are often treated empirically with amphotericin B or liposomal amphotericin B to prevent invasive fungal infections. Antifungal triazoles offer a potentially safer and effective alternative...
  91. ncbi The plant defensin, NaD1, enters the cytoplasm of Fusarium oxysporum hyphae
    Nicole L van der Weerden
    Department of Biochemistry, La Trobe University, Melbourne, Australia
    J Biol Chem 283:14445-52. 2008
    ..These results suggest that the activity of antifungal plant defensins may not be restricted to the hyphal membrane and that they enter cells and affect intracellular targets...
  92. ncbi Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation
    Dominique Sanglard
    Institute of Microbiology, University of Lausanne and University Hospital Center, 1011 Lausanne, Switzerland
    FEMS Yeast Res 9:1029-50. 2009
    ..b>Antifungal agents have demonstrated their efficacy by improving patient health in medicine...
  93. pmc Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)
    A Espinel-Ingroff
    VCU Medical Center, 3804 Dover Rd, Richmond, VA 23221, USA
    Antimicrob Agents Chemother 55:2855-9. 2011
    ..versicolor 0.25 and 0.5. Although caspofungin ECVs are not designed to predict the outcome of therapy, they may aid in the detection of strains with reduced antifungal susceptibility to this agent and acquired resistance mechanisms...
  94. ncbi Invasive trichosporonosis caused by Trichosporon asahii and other unusual Trichosporon species at a medical center in Taiwan
    Sheng Yuan Ruan
    Department of Internal Medicine, National Taiwan University Hospital Yun Lin Branch, Taiwan
    Clin Infect Dis 49:e11-7. 2009
    ..During the past 2 decades, invasive trichosporonosis has emerged as an opportunistic infectious disease in immunocompromised patients. However, no case series have been reported recently...
  95. pmc A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease
    Tran Th Chau
    Hospital for Tropical Diseases, Quan, Ho Chi Minh City, Vietnam
    BMC Infect Dis 10:199. 2010
    ..We describe a cohort of HIV uninfected Vietnamese patients with cryptococcal meningitis in whom underlying disease is uncommon, and relate presenting features of patients and the characteristics of the infecting species to outcome...
  96. ncbi An insight into the antifungal pipeline: selected new molecules and beyond
    Luis Ostrosky-Zeichner
    Division of Infectious Diseases, University of Texas Medical School at Houston, 6431 Fannin, MSB 2 112, Houston, Texas 77030, USA
    Nat Rev Drug Discov 9:719-27. 2010
    ..Few therapeutic products are currently in active development, and progression of therapeutic agents with fungus-specific mechanisms of action is of key importance...
  97. pmc Role of mitochondria in the pheromone- and amiodarone-induced programmed death of yeast
    Andrei I Pozniakovsky
    Max Planck Institute of Molecular Cell Biology and Genetics, 01307 Dresden, Germany
    J Cell Biol 168:257-69. 2005
    ..A novel mitochondrial protein required for thread-grain transition is identified...
  98. pmc Molecular mechanisms of primary resistance to flucytosine in Candida albicans
    William W Hope
    Immunocompromised Host Section POB, NCI, NIH CRC, Room 1 5700, 10 Center Dr, MSC 1100, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 48:4377-86. 2004
    ..A single resistant isolate, lacking the above polymorphism in FUR1, has a homozygous polymorphism in FCA1 that results in a glycine-to-aspartate substitution at position 28 in cytosine deaminase...
  99. ncbi Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis
    Eyal Robenshtok
    Department of Medicine E, Rabin Medical Center, Petah Tiqva, Israel
    J Clin Oncol 25:5471-89. 2007
    ..Many studies have evaluated the role of antifungal prophylaxis in cancer patients, with inconsistent conclusions...
  100. ncbi Plagiochin E, an antifungal bis(bibenzyl), exerts its antifungal activity through mitochondrial dysfunction-induced reactive oxygen species accumulation in Candida albicans
    Xiu Zhen Wu
    School of Pharmaceutical Sciences, Shandong University, No 44 West Wenhua Road, Jinan 250012, PR China
    Biochim Biophys Acta 1790:770-7. 2009
    ..Its antifungal mechanism is unknown. To elucidate the mechanism of action, its effect on mitochondria function in Candida albicans was studied...
  101. pmc Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan
    Jeniel E Nett
    Department of Medicine, University of Wisconsin, Madison, WI 53792, USA
    J Infect Dis 202:171-5. 2010
    ..These findings provide the genetic basis for how biofilm matrix production governs drug resistance by impeding drug diffusion and also identify a useful biofilm drug target...

Research Grants65

  1. Diverse Roles for RIC8 During G Protein Signaling in Fungi
    Katherine A Borkovich; Fiscal Year: 2012
    ..because RIC8 is conserved in filamentous fungi and G proteins are required for virulence in this class of organisms, the studies will also reveal new targets for antifungal agents that can be used to treat infections in humans.
  2. Biomarkers of Fusarium biofilm formation in vitro and in vivo
    PRANAB KUMAR MUKHERJEE; Fiscal Year: 2012
    ..Fusarium keratitis is not responsive to most antifungal agents, necessitating penetrating keratoplasty, with a high risk of failure and endophthalmitis...
  3. Mitochondrial function and antifungal photodynamic therapy
    Constantine G Haidaris; Fiscal Year: 2011
    ..Widespread resistance of Candida to the limited number of available antifungal agents demonstrates the urgent need for therapeutic alternatives...
  4. Identification of new compounds against fungal microbes
    Maurizio Del Poeta; Fiscal Year: 2013
    ..DESCRIPTION (provided by applicant): The goal of this project is to assess the therapeutic potential of novel antifungal agents, identified by our laboratory via screening the ChemBridge library, that target the synthesis of fungal ..
  5. Developing a New Therapeutic for the Treatment of Invasive Aspergillosis
    Mitchell W Mutz; Fiscal Year: 2013
    ..As a result, current antifungal agents have limited clinical efficacy, are poorly fungicidal in the host, are occasionally toxic, and are ..
  6. Manipulation of Host Angiogenesis as a Therapeutic Strategy against Invasive Pulm
    Dimitrios P Kontoyiannis; Fiscal Year: 2010
    ..Mortality from IA remains unacceptably high despite the availability of novel antifungal agents. The poor efficacy of antifungal drugs against IA may be linked to the propensity of Aspergillus species to ..
  7. Novel Antifungal Therapeutic Approaches
    Joseph Heitman; Fiscal Year: 2012
    ..b>Antifungal agents were limited to amphotericin B, flucytosine, and azoles, but now the candins, second-generation azoles, and ..
  8. A C.elegans high-throughput assay for the identification of new antifungal agents
    Eleftherios Mylonakis; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: There is an urgent need for the development of new antifungal agents to combat the increasing number of fungal infections and the development of antifungal resistance...
  9. Novel antifungals for Immunocompromised/HIV patients.
    ESTEBAN EDWARD MENA; Fiscal Year: 2011
    ..At present, there are only three classes of antifungal agents that are suitable for the treatment of AIDS-related fungal infections, but these medications are hampered by ..
  10. Pathogenesis of Cryptococcus Spores
    Christina M Hull; Fiscal Year: 2013
    ..Worldwide, treatment with antifungal agents results in ~80% survival, and individual prognoses are strongly influenced by the availability of antifungal ..
  11. Cell Wall Integrity Signaling in Yeast
    David E Levin; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): There is a growing need for safe and effective antifungal agents that stems from the rapidly increasing population of immunecompromised patients...
  12. Candida albicans Epithelial Cell Interactions and Oropharyngeal Disease
    Scott G Filler; Fiscal Year: 2013
    ..Azole antifungal agents are the current mainstay of therapy for oropharyngeal candidiasis...
  13. Role of transcriptional regulation in Aspergillus fumigatus drug resistance
    W Scott Moye-Rowley; Fiscal Year: 2012
    ..The high intrinsic resistance of A. fumigatus to currently available antifungal agents, coupled with the limited number of these drugs, makes drug resistance an especially acute issue in clinical ..
  14. Prevention of Invasive Candidiasis: PK, Safety, and Neurodevelopmental Outcomes
    Daniel K Benjamin; Fiscal Year: 2012
    ..pharmacokinetic study of fluconazole (Wade);and several studies (Benjamin, Reed, and Walsh) of other antifungal agents in the nursery including pharmacokinetic and pharmacodynamic studies of amphotericin B, liposomal ..
  15. Synthetic glycopeptide vaccines that enhance resistance to candidiasis
    Hong Xin; Fiscal Year: 2013
    ..Morbidity and mortality from invasive fungal infections remain unacceptably high despite availability of new antifungal agents, underscoring the need for more effective preventative strategies...
  16. 11th ASM Conference on Candida and candidiasis
    Scott G Filler; Fiscal Year: 2012
    ..focus on various key aspects of candidal infections, including environmental signaling, systems biology, antifungal agents and resistance, immune recognition, vaccines, morphogenesis, and biofilms...
  17. MICROBICIDAL SALIVARY HISTIDINE-RICH PROTEINS
    Frank G Oppenheim; Fiscal Year: 2012
    ..These studies promise to be of translational importance considering the paucity of available antifungal agents and the alarming emergence of fungal resistance to available antimycotics...
  18. Genome Integrity in Candida albicans
    Judith G Berman; Fiscal Year: 2013
    ..and/or LOH are common mechanisms used by pathogenic fungi to cope with assault from distinct classes of antifungal agents that use different mechanisms of action;b) Specific sub- populations of cells acquire high levels of ..
  19. Co-Delivery of Antifungal Agents: Toxicity and Efficacy in Invasive Candidiasis
    Glen S Kwon; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Despite recent increase in the number of antifungal agents available for the treatment of systemic fungal diseases, morbidity and mortality are substantial;noting that invasive candidiasis (IC) is ..
  20. Signal transduction in C. neoformans
    Jennifer K Lodge; Fiscal Year: 2012
    ..for cell growth, resistance to cell wall damaging agents and for virulence, and is induced in response to antifungal agents. For these reasons, it is critical to delineate the components of the pathway, determine how they interact, ..
  21. Hsp90 inhibitors to combat antifungal drug resistance.
    ESTEBAN EDWARD MENA; Fiscal Year: 2012
    ..Many of the emerging fungal pathogens that are resistant to the three classes of antifungal agents for AID-s-related infections are becoming more common and are associated with higher rates of mortality...
  22. Cell Wall Biogenesis in Candida albicans
    Stephen J Free; Fiscal Year: 2013
    ..of the cross-linking enzymes'substrate requirements will play a key role in the development of antifungal agents that act as inhibitors of these cross-linking enzymes...
  23. Biosynthesis of HSAF, an antifungal natural product with a novel mode of action
    Liangcheng Du; Fiscal Year: 2009
    ..Thus, HSAF has an unprecedented mode of action and a new chemistry, which are criteria for new antifungal agents. However, chemical total synthesis of HSAF is not feasible for commercial production due to its highly ..
  24. Antifungal drug target prioritization using Cryptococcus neoformans
    Alexander Idnurm; Fiscal Year: 2013
    ..The discovery of these essential genes represents new avenues for the development of antifungal agents.
  25. In vivo profiling for oral candidiasis drug target discovery
    David A Schofield; Fiscal Year: 2010
    ..Specific Aim 2 will demonstrate that oligonucleotides can function as antifungal agents against Candida species in vitro...
  26. Targeting virulence against oral candidiasis in HIV/AIDS
    Jose L Lopez-Ribot; Fiscal Year: 2013
    ..antifungal therapy for the treatment of OPC has many shortcomings, due to the limited armamentarium of antifungal agents, the toxicity displayed by some of the current therapies and, principally, the emergence of resistance to ..
  27. Synthesis and discovery of biologically active cell-permeable cyclic peptides
    R Scott Lokey; Fiscal Year: 2012
    ..We expect that new antibiotics and antifungal agents will emerge from this project.
  28. New Drugs for Opportunistic Infections
    Alice M Clark; Fiscal Year: 2013
    ..work will yield new prototype lead compounds that will serve as templates for development of new classes of antifungal agents, as templates for the development of new drugs to be used in combination with existing antifungal agents to ..
  29. Studies on NikD, a Nikkomycin Biosynthetic Enzyme
    MARILYN S JORNS; Fiscal Year: 2010
    ..Nikkomycins are peptidyl nucleosides that act as antifungal agents by blocking the biosynthesis of chitin, the second most abundant polysaccharide in Nature...
  30. Biology of Fungal Melanin
    Arturo Casadevall; Fiscal Year: 2013
    ..In addition, melanins reduce the susceptibility of fungi to polyene and echinocandin type antifungal agents and thus represent an important component of acquired drug resistance...
  31. Genomic Database for Candida Albicans
    GAVIN J SHERLOCK; Fiscal Year: 2013
    ..Thus, there is a need for alternative antifungal agents that are more specifically directed at the fungal cell and less toxic to human cells, and thus it is vital ..
  32. Linking Triazole Resistance and Fitness in Aspergillus fumigatus
    David S Perlin; Fiscal Year: 2013
    ..represent first-line therapy for all forms of aspergillosis and comprise the only orally active group of antifungal agents. The rapid increase in triazole resistant Aspergillus infections is a growing public health and patient ..
  33. CLASS II AMINOACYL-TRNA SYNTHETASE SUBSTRATE RECOGNITION
    KARIN M MUSIER-FORSYTH; Fiscal Year: 2012
    ..Due to their essential function, these enzymes are also promising targets for the development of antibiotics and antifungal agents.
  34. A New Class of Broad Spectrum Antifungal Agents
    Glen Palmer; Fiscal Year: 2013
    ..The goal of this proposal is to establish a new class of antifungal agents which act via a distinct mechanism from existing therapies...
  35. ANTIFUNGAL RESPONSE--MDR INDUCTION
    Thomas Edlind; Fiscal Year: 2002
    ..The Specific Aims of this proposal are to examine the: (1) Spectrum of MDR induction. New antifungal agents and anti-infective agents commonly used in immunocompromised patients will be tested for C...
  36. Natural Products for Treatment of Emergent AIDS-Related Pathogens
    Tadeusz F Molinski; Fiscal Year: 2013
    ..investigations have evolved into directions towards new goals, particularly methodology for discovery of antifungal agents for emergent pathogens, for example, Cryptococcus gatti, C. neoformans, and C...
  37. Role of Antimicrobial Peptides at the Ocular Surface
    Alison M McDermott; Fiscal Year: 2013
    ..Also in specific aim 3, the potential of AMP-tethered liposomes as novel topical antifungal agents will be addressed...
  38. ORAL CONTROLLED-RELEASE DELIVERY SYSTEMS
    H Rawls; Fiscal Year: 1991
    ..The need for antifungal agents is to control opportunistic oral candidiasis, an infection that frequently strikes the elderly, denture ..
  39. Cellular Mechanisms Governing an Invasive Aspergillosis Virulence Factor
    Graeme S Garvey; Fiscal Year: 2010
    ..Current treatments with antifungal agents is often ineffective with invasive aspergillosis mortality rates still unacceptably high, it is therefore ..
  40. High throughput identification and quantification of fungi using high resolution
    Robert A Akins; Fiscal Year: 2010
    ..Individual fungal species are resistant to some of the growing list of antifungal agents, or have acquired resistance mutations that make specific agents ineffective or less effective...
  41. Chemically diverse antimicrobials from silent biosynthetic pathways
    ROBERT HENRY CICHEWICZ; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: These studies are designed to address the need for new antibacterial and antifungal agents for treating a wide range of microbial pathogens...
  42. Biology and Drug Resistance of Candida Biofilms
    Mahmoud Ghannoum; Fiscal Year: 2005
    ..albicans isolates obtained from denture stomatitis patients, and to study the effect of antifungal agents on the growth kinetics of C. albicans bioflims...
  43. Fungal infections and tolerogenic immunosuppression
    Fernanda Silveira; Fiscal Year: 2009
    ..Although one strategy of prevention is use of prophylactic antifungal agents, an alternative approach is to find a means of diagnosis of fungal infections while they are still at a ..
  44. A NOVEL TARGET FOR THE DEVELOPMENT OF ANTIFUNGAL AGENTS
    Corey Nislow; Fiscal Year: 2001
    ..There is a clear need for more effective antifungal agents. To address this need, we plan to exploit the opportunity to discover antifungal compounds with a novel ..
  45. Mechanism of clinical resistance to echinocandin antifungal drugs
    David S Perlin; Fiscal Year: 2011
    ..The widespread use of antifungal agents has resulted in selection of naturally resistant fungal species, as well as the emergence of resistance in ..
  46. Antifungal Denture Adhesive Film for Oral Candidiasis
    THOMAS GERDING; Fiscal Year: 2004
    ..This study will test the hypothesis that novel denture adhesive films containing antifungal agents will improve treatment outcomes of oral candidiasis in denture patients...
  47. REDUCED DRUG INTERACTIONS OF AZOLE ANTIFUNGAL DRUGS
    Joseph Gal; Fiscal Year: 2003
    ..The "azoles" ketoconazole and itraconazole are important and widely-used oral antifungal agents, but the use of these drugs is limited by adverse side effects and serious drug-drug interactions...
  48. Chemistry of Reactive Intermediates Generated from Benzothiazole Derived Drug Can
    Michael Novak; Fiscal Year: 2009
    ..have been under rapid development as anti-tumor, antimicrobial, and antifungal agents and as radiopharmaceuticals for binding and in vivo imaging of A?-plaques, one of the earliest pathological ..
  49. Signaling Pathways in Yeast Azole Response
    Thomas Edlind; Fiscal Year: 2005
    ..There has been a parallel development of new antifungal agents. In particular, azoles that inhibit lanosterol demethylase and hence ergosterol biosynthesis...
  50. Rechargeable Long-term Antifungal Denture Materials
    Yuyu Sun; Fiscal Year: 2009
    ..the quantity of antifungals released when the drugs are most needed, and the use and rotation of multiple antifungal agents in the initial binding and subsequent recharging treatments to improve inhibitory potency and minimize the ..
  51. FOCUSED PARALLEL SYNTHESIS OF DICATION ANTIFUNGAL AGENTS
    Richard Tidwell; Fiscal Year: 2003
    ..and pharmacology of dicationic compounds clearly show that these molecules have great potential as antifungal agents. The current proposal will expand these initial studies by synthesizing over 2,400 related molecules per ..
  52. Iontophoresis to Improve Nail Disease Treatment
    KEVIN S LI; Fiscal Year: 2012
    ..The current method of treatment for onychomycosis is oral systemic administration of antifungal agents, which has long treatment regimen and is not very effective...
  53. High throughput S. cerevisiae HAM, GWA &QT/QTL architecture
    Eric A Stone; Fiscal Year: 2013
    ..QTGs controlling resistance to 5- fluoropyrimidines, which are clinically used anti-cancer and/or antifungal agents, and membrane stressors, many of which are clinically used antifungal agents...
  54. The presence of a bacterial metabolic pathway in eukaryotic fungi
    KERRY SCOT SMITH; Fiscal Year: 2010
    ..animals, and plants may allow these enzymes to be investigated as potential targets for development of antifungal agents in the future...
  55. AIDS Opportunistic Pathogens/Fungal Cell Wall Drug Targets
    Brendan Cormack; Fiscal Year: 2006
    ..A third of HIV sero-positive and 90% of AIDS patients will present with oropharyngeal candidiasis. Few antifungal agents are available for treatment and to compound the problem, some species of Candida, notably Candida glabrata, ..
  56. Ambruticin for Aspergillus
    Leonard Katz; Fiscal Year: 2005
    ..Other in vitro experiments will include the determination of synergy or antagonism of ambruticin with other antifungal agents, and determination of the post-antibiotic effect of these compounds...
  57. Planning a Multicenter Oral Itraconazole Trial in Chronic Rhinosinusitis Patients
    Hirohito Kita; Fiscal Year: 2007
    ..fungal etiology of CRS, several controlled and open-label clinical trials have previously tested intranasal antifungal agents as a potential therapy for CRS. However, the results from these studies are conflicting...
  58. GLYCOSYLTRANSFERASE INHIBITORS AS ANTIFUNGAL AGENTS
    Nathaniel Finney; Fiscal Year: 2003
    ....
  59. Cell wall biogenesis in Cryptococcus neoformans
    Deborah Fox; Fiscal Year: 2004
    ..In particular, members of the echinocandin class of antifungal agents are potent inhibitors of cell wall synthesis in many pathogenic fungi...
  60. HISTIDINE-RICH POLYPEPTIDES, ORAL CANDIDIASIS AND AIDS
    JERRY POLLOCK; Fiscal Year: 1992
    ..upon the family of the salivary histidine-rich polypeptides (HRPs) which are thought by us to be the natural antifungal agents of the mouth...
  61. MECHANISM OF ANTIBODY PROTECTION AGAINST C. NEOFORMANS
    Sherie Morrison; Fiscal Year: 2007
    ..monoclonal antibodies can prolong the life of lethally infected mice and increase the effectiveness of antifungal agents in vivo...
  62. Actin-binding proteins as novel antifungal targets
    Corey Nislow; Fiscal Year: 2001
    ..Hence, there is a clear need for more effective antifungal agents. To address this need, we plan to discover antifungal therapeutics with novel mechanisms of action by ..
  63. ANTIFUNGALS FROM MARINE INVERTEBRATES--AIDS ADJUVANTS
    Tadeusz F Molinski; Fiscal Year: 2010
    ..Natural products are represented among clinically useful antifungal agents. Marine invertebrates, particularly Porifera (sponges), produce chemically diverse libraries of natural ..
  64. PRACTICAL CHEMICAL SYNTHESIS OF COMPLEX ALKALOIDS
    LARRY OVERMAN; Fiscal Year: 2009
    ..only 30% homology with the corresponding human enzyme, it represents a novel lead in the search for new antifungal agents. Our ongoing studies in the crambescidin and batzelladine alkaloid areas focus on identifying structurally ..
  65. Synthesis and Study of Amphotericin B Derivatives
    Martin D Burke; Fiscal Year: 2013
    ..action of this clinically vital antifungal agent, generate promising candidates for further development as antifungal agents with an improved therapeutic index, drive the continued development of a highly efficient and flexible ..